Overview

Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
To determine the efficacy as measured by objective tumor response of first-line treatment of metastatic melanoma with bevacizumab monotherapy
Phase:
Phase 2
Details
Lead Sponsor:
Haukeland University Hospital
Collaborators:
Hoffmann-La Roche
Norwegian Cancer Society
Treatments:
Bevacizumab